Developer docs
API playgroundTry for free, no card

Search company profiles

Carterra

Full company profile

uuid00029fg

Namestring
Carterra
Legal namestring
Carterra, Inc.
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Carterra is a privately held life science tools company founded in 2005 and headquartered in Salt Lake City, Utah, that develops and manufactures High-Throughput Surface Plasmon Resonance (HT-SPR) instruments used by pharmaceutical and biotechnology companies for antibody screening, epitope binning, kinetic profiling, and small-molecule interaction analysis in drug discovery workflows. The company's technology platform combines proprietary flow-printing microfluidics (a 96-channel printhead and Single Flow Cell cartridge, originated at the University of Utah) with imaging-based SPR detection that monitors up to 384-192 simultaneous interactions in real time, protected by a portfolio of at least eight granted US patents. Its product line spans four instruments - the LSA, LSAXT, Ultra, and the February 2026-launched Vega (the industry's first 48-channel HT-SPR delivering 12x the throughput of 8-channel systems) - complemented by proprietary biosensor chips (HC, CMD, NiNTA, streptavidin, Protein A/G), Navigator experimental setup software, and Kinetics and Epitope Data Analysis Software. Carterra reports instruments installed across all 20/20 top pharmaceutical companies and at named accounts including Pfizer, Merck, GSK, Eli Lilly, Twist Bioscience, Generate Biomedicines, Ligand Pharmaceuticals, and Fred Hutchinson Cancer Research Center.

The company monetizes through direct enterprise sales of instruments (quote-based pricing via phone and contact forms), recurring revenue from proprietary sensor chips, printhead and SFC cartridges, licensed software with periodic updates (latest release V.2.0.0.5078 in October 2025), service contracts, and an international distributor network supported by regional offices in Walnut Creek, Andover, Munich/Planegg, and Manchester (UK). Go-to-market combines a direct enterprise field-sales motion with annual Carterra Symposia in San Francisco, Boston, and Amsterdam, major-conference presence (SLAS2025/SLAS2026 where Vega was announced), testimonial-led content marketing, and active LinkedIn and YouTube channels. Carterra is positioning itself explicitly for AI/ML-driven drug discovery, with William Blair analysts naming it a top life science tools provider for AI drug discovery in April 2026 and a strategic partnership with Generate Biomedicines embedding its LSA platform in an ML-driven protein design workflow.

Carterra operates from offices in Salt Lake City (HQ), Walnut Creek, Andover, Munich/Planegg, and Manchester, with 51-100 employees. The company has raised approximately $48M+ across disclosed rounds from 2012 to 2021 from investors including PerkinElmer, Telegraph Hill Partners, Ballast Point Ventures, Frazier VC, and PC Squared LLC; no funding rounds are disclosed since 2021. Leadership includes CEO Josh Eckman, founder and Senior Scientist James Smith, VP of Marketing and Product Christopher M. Silva, VP of R&D Ben Brooks, and Director of Research Bruce Gale (the University of Utah professor whose lab originated the core flow-printing technology). Revenue, ownership, and detailed financial metrics are not publicly disclosed.

Short descriptiontext

Carterra is a privately held life science tools company that develops High-Throughput Surface Plasmon Resonance (HT-SPR) instruments - including the LSA, LSAXT, Ultra, and Vega platforms - used by pharmaceutical and biotechnology companies for high-throughput antibody screening, epitope binning, and small-molecule interaction analysis in drug discovery workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
high-throughput surface plasmon resonance, antibody screening instruments, epitope binning platforms, label-free biomolecular interaction, biosensor consumables
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
High-Throughput Surface Plasmon Resonance (HT-SPR) Instruments for Drug Discovery
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1HT-SPR Instrumentation Sales
TypeHardware Sales
Description

Sale of high-throughput surface plasmon resonance instruments including Carterra Vega, Ultra, LSAXT, and LSA platforms. Instruments are sold directly through Carterra's sales team and through distributors. First unit of new platforms typically ships to Key Opinion Leaders at top pharmaceutical companies.

carterra-bio.com
2Sensor Chips and Consumables
TypeHardware Sales
Description

Sale of proprietary biosensor chip chemistries including HC series (linear polycarboxylate), CMD series (carboxymethylated dextran), NiNTA, streptavidin, Protein A, and Protein A/G surfaces. Consumables also include the 96-channel printhead cartridges, SFC cartridges, and other assay-specific reagents.

carterra-bio.com
3Software Licenses and Updates
TypeSubscription Recurring
Description

Kinetics and Epitope Data Analysis Software sold as licenses with periodic updates. Software version V.2.0.0.5078 released October 30, 2025. Customer portal provides access to software updates, user manuals, and training videos upon registration.

carterra-bio.com
4Service, Support, and Training
TypeProfessional Services
Description

Service and support provided via dedicated support team (1-844-642-7635, Option 3) with hours 8:00 am – 6:00 pm MT. Application Training Program offered. Technical support updates distributed to customers.

carterra-bio.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Carterra develops, manufactures, and sells High-Throughput Surface Plasmon Resonance (HT-SPR) instruments — Carterra Vega, Ultra, LSAXT, and LSA — that enable parallel, label-free characterization of biomolecular interactions for antibody and small molecule drug discovery. The company also supplies proprietary biosensor sensor chips, printhead and SFC cartridges, and data analysis software (Kinetics, Epitope, Navigator) used by pharmaceutical, biotechnology, and AI drug discovery customers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Saves tens of millions of dollars and months of development time while reducing risk of costly clinical failures by enabling primary screening and target/off-target assessment earlier in drug discovery
+6 more records
Product overview1 text field

Carterra offers a portfolio of four High-Throughput Surface Plasmon Resonance (HT-SPR) instruments for antibody and small molecule drug discovery: Carterra Vega (industry's first 48-channel platform for screening >20,000 compounds daily), Carterra Ultra (most versatile platform for small molecule and fragment analysis with enhanced sensitivity), Carterra LSAXT (enhanced data quality for antibody discovery), and Carterra LSA (detailed antibody kinetic and epitope binning characterization). The ecosystem includes specialized sensor chips in various chemistries (carboxymethylated dextran, NiNTA, streptavidin, Protein A/G), Kinetics Data Analysis Software for processing up to 1152 kinetic interactions, Epitope Data Analysis Software for 384x384 binning studies, and AI/ML tools for generating data to train and validate computational drug discovery models.

Product and service7 records
1Carterra Vega
CategoryHT-SPR Instruments
Description

Industry's first 48-channel high-throughput surface plasmon resonance (HT-SPR) instrument delivering 12-fold higher throughput than existing systems, enabling screening of more than 20,000 small molecule interactions per day for drug discovery workflows. Targets pharmaceutical and biotechnology drug discovery customers.

2Carterra Ultra
CategoryHT-SPR Instruments
Description

Most versatile HT-SPR platform for small molecule and biological discovery with enhanced sensitivity, expanded thermal options, and advanced microfluidics. Supports interrogation of multiple proteins and off-target binding in parallel with up to 192 ligand array spots. Targets drug discovery teams needing analyte sensitivity down to 100-500 Da.

3Carterra LSAXT
CategoryHT-SPR Instruments
Description

HT-SPR platform with enhanced sensitivity and faster data collection rate enabling PROTACs, protein-protein inhibitors, kinase, and cytokine screening and characterization. Delivers up to 100x the data in 10% of the time with 1% of sample requirements versus other systems. Targets pharmaceutical and biotech customers.

4Carterra LSA
CategoryHT-SPR Instruments
Description

Versatile high-throughput monoclonal antibody characterization platform combining patented flow printing microfluidics with HT-SPR detection. Delivers up to 100x the data in 10% of the time with 1% of sample requirements for detailed antibody kinetic and epitope binning analysis. Used by pharma, biotech, CROs, and research institutions including Fred Hutchinson Cancer Research Center and University of Pennsylvania.

5Sensor Chips
CategoryConsumables
Description

Broad range of proprietary biosensor chip chemistries including linear polycarboxylate (HC30M, HC200M), carboxymethylated dextran (CMDP, CMD50M, CMD200M, CMD500M), NiNTA (NiCMDP, NiHC200M), streptavidin (SAP, SAHC30M, SAD200M, RSA200M), Protein A (PAHC200M), and Protein A/G (PAGP, PAGHC30M, PAGHC200M) surfaces for diverse HT-SPR applications. Sold as recurring consumables for installed Carterra instruments.

6Kinetics Data Analysis Software
CategorySoftware
Description

High-throughput kinetics screening software that enables kinetic and steady state affinity analysis on thousands of interactions with automatic data flagging, advanced analysis features for trend and replicate display, and ability to process up to 1,152 samples per unattended run. Current version V.2.0.0.5078 released October 30, 2025. Licensed to pharmaceutical, biotech, and academic customers running HT-SPR assays.

7Epitope Data Analysis Software
CategorySoftware
Description

Software designed to process massive datasets from HT-SPR epitope binning studies where 384 ligands can be tested against 384 analytes, enabling rapid analysis and visualization with heat maps, dendrograms, and network plots. Current version V.2.0.0.5078. Licensed to antibody discovery teams at pharma, biotech, CROs, and research institutions.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierNotableTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Charles River announced a partnership with Synthace at SLAS2026. While this is a Charles River partnership rather than Carterra's directly, Carterra was featured alongside Charles River at SLAS2026 as part of the high-throughput screening ecosystem.

Strategic tierCoreTypeTechnology or Integration
Description

Carterra has partnered with Revvity to integrate its HT-SPR data with Revvity's Signals VitroVivo (formerly Signals Screening) software v2.7 or later. The integration provides a single repository for organizing HT-SPR experimental data, enables comparison with orthogonal methods, and supports built-in intuitive data analysis and search tools. Integration with TIBCO Spotfire is also supported for comprehensive analytics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Generate Biomedicines uses Carterra's LSA platform as an integral part of its machine learning-driven protein design platform. The partnership generates the high-resolution binding data at high throughput needed to train and validate computational protein design models.

4KOLs from Three Major Pharmaceutical Companies and Large CRO
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Carterra Vega platform was developed in collaboration with Key Opinion Leaders from three major pharmaceutical companies and a large CRO. The first Vega unit shipped in Q1 2026 to a KOL at a top 10 pharmaceutical company.

carterra-bio.com
5Dragonfly Therapeutics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dragonfly Therapeutics uses Carterra's LSAXT platform for bispecific antibody discovery and Fc-gamma receptor binding characterization. The case study demonstrated that HT-SPR delivered data quality nearly indistinguishable from their existing biosensor while completing a full characterization in less than a day versus an entire week with traditional methods.

carterra-bio.com
6International Distributor Network
Strategic tierNotableTypeChannel Partner/ Reseller/ Distributor
Description

Carterra maintains a global distributor network for international markets, with dedicated distributor contact information available at carterra-bio.com/distributor-contact-information/. Regional offices in the US, Germany, and UK support these distribution relationships.

carterra-bio.com
Strategic tierFoundationalTypeStrategic or Co-development Partner
Description

Carterra's patented flow printing technology was invented in the lab of Prof. Bruce Gale at the University of Utah Department of Mechanical Engineering. The technology uses a network of microchannels enabling flow-based array printing of proteins and antibodies on sensor surfaces.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Wasatch Microfluidics / University of Utah SPR spinouts
TypeEmerging player
Description

Academic and early-stage commercial groups continuing to innovate in SPR microfluidics and array-based biosensing (drawn from the same University of Utah ecosystem that birthed Carterra's flow-printing IP). These emerging entrants represent a long-tail competitive threat as SPR technology matures.

TypeBroad incumbent
Description

Bruker manufactures a broad range of life-science analytical instruments including mass spectrometry and SPR systems, serving the same pharmaceutical and academic research customers as Carterra with a much larger and more diversified product portfolio.

TypeBroad incumbent
Description

Sartorius (including the legacy FortéBio Octet bio-layer interferometry line) competes with Carterra in label-free protein interaction analysis for antibody screening and bioprocess analytics, serving overlapping pharma/biotech customers with a broader bioprocessing portfolio.

TypeDirect peer
Description

Cytiva's Biacore line is the dominant surface plasmon resonance (SPR) platform in pharmaceutical and academic labs. As the incumbent in label-free biomolecular interaction analysis, Biacore directly competes with Carterra's LSA, LSAXT, Ultra, and Vega systems across the same pharma and biotech customer base.

TypeRegional player
Description

Molecular Devices (a Danaher operating company) offers microplate readers, washers, and label-free detection platforms used in drug discovery. Its label-free and high-throughput screening products compete with Carterra's HT-SPR for the same antibody screening and characterization workflows.

TypeOthers
Description

Malvern Panalytical provides analytical instrumentation for material characterization, including particle sizing and molecular interaction tools. While it does not directly compete in HT-SPR, it addresses adjacent biophysical characterization needs for the same biotech and pharma R&D customers.

TypeBroad incumbent
Description

Thermo Fisher offers a wide suite of life-science instruments, consumables, and analytical tools used in drug discovery workflows. While not a direct SPR competitor, it sells alternative characterization and high-throughput screening platforms to the same pharma/biotech buyer base.

TypeBroad incumbent
Description

Agilent provides analytical instruments (mass spectrometry, chromatography, plate readers) used in pharmaceutical discovery and characterization. It competes with Carterra for share of biopharma R&D lab budgets and increasingly offers label-free and high-throughput screening solutions.

TypeBroad incumbent
Description

Revvity is both an integration partner of Carterra (Signals VitroVivo software) and a broader life-science instruments and reagents supplier, including the legacy PerkinElmer analytical portfolio. It competes for the same pharma discovery and screening budgets and provides complementary and overlapping analytical platforms.

TypeBroad incumbent
Description

Waters is a leading analytical instrument manufacturer (chromatography, mass spectrometry, sample management) used in pharmaceutical discovery and QC. It addresses overlapping biopharma R&D customers as Carterra, though with separation- and characterization-focused tools rather than SPR.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers18 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Carterra

High-Throughput Surface Plasmon Resonance (HT-SPR) Instruments for Drug Discoverycarterra-bio.com

Carterra is a privately held life science tools company that develops High-Throughput Surface Plasmon Resonance (HT-SPR) instruments - including the LSA, LSAXT, Ultra, and Vega platforms - used by pharmaceutical and biotechnology companies for high-throughput antibody screening, epitope binning, and small-molecule interaction analysis in drug discovery workflows.

What Carterra does

Carterra is a privately held life science tools company founded in 2005 and headquartered in Salt Lake City, Utah, that develops and manufactures High-Throughput Surface Plasmon Resonance (HT-SPR) instruments used by pharmaceutical and biotechnology companies for antibody screening, epitope binning, kinetic profiling, and small-molecule interaction analysis in drug discovery workflows. The company's technology platform combines proprietary flow-printing microfluidics (a 96-channel printhead and Single Flow Cell cartridge, originated at the University of Utah) with imaging-based SPR detection that monitors up to 384-192 simultaneous interactions in real time, protected by a portfolio of at least eight granted US patents. Its product line spans four instruments - the LSA, LSAXT, Ultra, and the February 2026-launched Vega (the industry's first 48-channel HT-SPR delivering 12x the throughput of 8-channel systems) - complemented by proprietary biosensor chips (HC, CMD, NiNTA, streptavidin, Protein A/G), Navigator experimental setup software, and Kinetics and Epitope Data Analysis Software. Carterra reports instruments installed across all 20/20 top pharmaceutical companies and at named accounts including Pfizer, Merck, GSK, Eli Lilly, Twist Bioscience, Generate Biomedicines, Ligand Pharmaceuticals, and Fred Hutchinson Cancer Research Center.

The company monetizes through direct enterprise sales of instruments (quote-based pricing via phone and contact forms), recurring revenue from proprietary sensor chips, printhead and SFC cartridges, licensed software with periodic updates (latest release V.2.0.0.5078 in October 2025), service contracts, and an international distributor network supported by regional offices in Walnut Creek, Andover, Munich/Planegg, and Manchester (UK). Go-to-market combines a direct enterprise field-sales motion with annual Carterra Symposia in San Francisco, Boston, and Amsterdam, major-conference presence (SLAS2025/SLAS2026 where Vega was announced), testimonial-led content marketing, and active LinkedIn and YouTube channels. Carterra is positioning itself explicitly for AI/ML-driven drug discovery, with William Blair analysts naming it a top life science tools provider for AI drug discovery in April 2026 and a strategic partnership with Generate Biomedicines embedding its LSA platform in an ML-driven protein design workflow.

Carterra operates from offices in Salt Lake City (HQ), Walnut Creek, Andover, Munich/Planegg, and Manchester, with 51-100 employees. The company has raised approximately $48M+ across disclosed rounds from 2012 to 2021 from investors including PerkinElmer, Telegraph Hill Partners, Ballast Point Ventures, Frazier VC, and PC Squared LLC; no funding rounds are disclosed since 2021. Leadership includes CEO Josh Eckman, founder and Senior Scientist James Smith, VP of Marketing and Product Christopher M. Silva, VP of R&D Ben Brooks, and Director of Research Bruce Gale (the University of Utah professor whose lab originated the core flow-printing technology). Revenue, ownership, and detailed financial metrics are not publicly disclosed.

Carterra firmographics

Firmographics
Name
Carterra
Legal name
Carterra, Inc.
Website
https://carterra-bio.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Carterra is a privately held life science tools company that develops High-Throughput Surface Plasmon Resonance (HT-SPR) instruments - including the LSA, LSAXT, Ultra, and Vega platforms - used by pharmaceutical and biotechnology companies for high-throughput antibody screening, epitope binning, and small-molecule interaction analysis in drug discovery workflows.
Ownership category
akta.pro rank

Carterra industry classification

Industry
Product category
High-Throughput Surface Plasmon Resonance (HT-SPR) Instruments for Drug Discovery
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)

Keywords

  • High-throughput surface plasmon resonance
  • Antibody screening instruments
  • Epitope binning platforms
  • Label-free biomolecular interaction
  • Biosensor consumables

Where Carterra is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Carterra business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. HT-SPR Instrumentation Sales: Sale of high-throughput surface plasmon resonance instruments including Carterra Vega, Ultra, LSAXT, and LSA platforms. Instruments are sold directly through Carterra's sales team and through distributors. First unit of new platforms typically ships to Key Opinion Leaders at top pharmaceutical companies.
  2. Sensor Chips and Consumables: Sale of proprietary biosensor chip chemistries including HC series (linear polycarboxylate), CMD series (carboxymethylated dextran), NiNTA, streptavidin, Protein A, and Protein A/G surfaces. Consumables also include the 96-channel printhead cartridges, SFC cartridges, and other assay-specific reagents.
  3. Software Licenses and Updates: Kinetics and Epitope Data Analysis Software sold as licenses with periodic updates. Software version V.2.0.0.5078 released October 30, 2025. Customer portal provides access to software updates, user manuals, and training videos upon registration.
  4. Service, Support, and Training: Service and support provided via dedicated support team (1-844-642-7635, Option 3) with hours 8:00 am – 6:00 pm MT. Application Training Program offered. Technical support updates distributed to customers.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels10 records

Carterra product offering

Product offering

Core offering

Carterra develops, manufactures, and sells High-Throughput Surface Plasmon Resonance (HT-SPR) instruments — Carterra Vega, Ultra, LSAXT, and LSA — that enable parallel, label-free characterization of biomolecular interactions for antibody and small molecule drug discovery. The company also supplies proprietary biosensor sensor chips, printhead and SFC cartridges, and data analysis software (Kinetics, Epitope, Navigator) used by pharmaceutical, biotechnology, and AI drug discovery customers globally.

Product overview

Carterra offers a portfolio of four High-Throughput Surface Plasmon Resonance (HT-SPR) instruments for antibody and small molecule drug discovery: Carterra Vega (industry's first 48-channel platform for screening >20,000 compounds daily), Carterra Ultra (most versatile platform for small molecule and fragment analysis with enhanced sensitivity), Carterra LSAXT (enhanced data quality for antibody discovery), and Carterra LSA (detailed antibody kinetic and epitope binning characterization). The ecosystem includes specialized sensor chips in various chemistries (carboxymethylated dextran, NiNTA, streptavidin, Protein A/G), Kinetics Data Analysis Software for processing up to 1152 kinetic interactions, Epitope Data Analysis Software for 384x384 binning studies, and AI/ML tools for generating data to train and validate computational drug discovery models.

Differentiator

Problem solved

Functional benefit

Products and services

  • Carterra Vega Industry's first 48-channel high-throughput surface plasmon resonance (HT-SPR) instrument delivering 12-fold higher throughput than existing systems, enabling screening of more than 20,000 small molecule interactions per day for drug discovery workflows. Targets pharmaceutical and biotechnology drug discovery customers.
  • Carterra Ultra Most versatile HT-SPR platform for small molecule and biological discovery with enhanced sensitivity, expanded thermal options, and advanced microfluidics. Supports interrogation of multiple proteins and off-target binding in parallel with up to 192 ligand array spots. Targets drug discovery teams needing analyte sensitivity down to 100-500 Da.
  • Carterra LSAXT HT-SPR platform with enhanced sensitivity and faster data collection rate enabling PROTACs, protein-protein inhibitors, kinase, and cytokine screening and characterization. Delivers up to 100x the data in 10% of the time with 1% of sample requirements versus other systems. Targets pharmaceutical and biotech customers.
  • Carterra LSA Versatile high-throughput monoclonal antibody characterization platform combining patented flow printing microfluidics with HT-SPR detection. Delivers up to 100x the data in 10% of the time with 1% of sample requirements for detailed antibody kinetic and epitope binning analysis. Used by pharma, biotech, CROs, and research institutions including Fred Hutchinson Cancer Research Center and University of Pennsylvania.
  • Sensor Chips Broad range of proprietary biosensor chip chemistries including linear polycarboxylate (HC30M, HC200M), carboxymethylated dextran (CMDP, CMD50M, CMD200M, CMD500M), NiNTA (NiCMDP, NiHC200M), streptavidin (SAP, SAHC30M, SAD200M, RSA200M), Protein A (PAHC200M), and Protein A/G (PAGP, PAGHC30M, PAGHC200M) surfaces for diverse HT-SPR applications. Sold as recurring consumables for installed Carterra instruments.
  • Kinetics Data Analysis Software High-throughput kinetics screening software that enables kinetic and steady state affinity analysis on thousands of interactions with automatic data flagging, advanced analysis features for trend and replicate display, and ability to process up to 1,152 samples per unattended run. Current version V.2.0.0.5078 released October 30, 2025. Licensed to pharmaceutical, biotech, and academic customers running HT-SPR assays.
  • Epitope Data Analysis Software Software designed to process massive datasets from HT-SPR epitope binning studies where 384 ligands can be tested against 384 analytes, enabling rapid analysis and visualization with heat maps, dendrograms, and network plots. Current version V.2.0.0.5078. Licensed to antibody discovery teams at pharma, biotech, CROs, and research institutions.

Quantifiable outcome

  • Saves tens of millions of dollars and months of development time while reducing risk of costly clinical failures by enabling primary screening and target/off-target assessment earlier in drug discovery
  • +6 more outcomes

Companies that use Carterra

Customer profile

Named customers18 records

Segments5 records

Ideal customer profiles4 records

Carterra technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature8 records

Carterra partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered notable, core and foundational.

  • Charles River LaboratoriesnotableStrategic or Co-development Partner · 1 January 2026Charles River announced a partnership with Synthace at SLAS2026. While this is a Charles River partnership rather than Carterra's directly, Carterra was featured alongside Charles River at SLAS2026 as part of the high-throughput screening ecosystem.
  • Revvity (Signals VitroVivo Software)coreTechnology or IntegrationCarterra has partnered with Revvity to integrate its HT-SPR data with Revvity's Signals VitroVivo (formerly Signals Screening) software v2.7 or later. The integration provides a single repository for organizing HT-SPR experimental data, enables comparison with orthogonal methods, and supports built-in intuitive data analysis and search tools. Integration with TIBCO Spotfire is also supported for comprehensive analytics.
  • Generate BiomedicinescoreStrategic or Co-development PartnerGenerate Biomedicines uses Carterra's LSA platform as an integral part of its machine learning-driven protein design platform. The partnership generates the high-resolution binding data at high throughput needed to train and validate computational protein design models.
  • KOLs from Three Major Pharmaceutical Companies and Large CROcoreStrategic or Co-development PartnerThe Carterra Vega platform was developed in collaboration with Key Opinion Leaders from three major pharmaceutical companies and a large CRO. The first Vega unit shipped in Q1 2026 to a KOL at a top 10 pharmaceutical company.
  • Dragonfly TherapeuticscoreStrategic or Co-development PartnerDragonfly Therapeutics uses Carterra's LSAXT platform for bispecific antibody discovery and Fc-gamma receptor binding characterization. The case study demonstrated that HT-SPR delivered data quality nearly indistinguishable from their existing biosensor while completing a full characterization in less than a day versus an entire week with traditional methods.
  • International Distributor NetworknotableChannel Partner/ Reseller/ DistributorCarterra maintains a global distributor network for international markets, with dedicated distributor contact information available at carterra-bio.com/distributor-contact-information/. Regional offices in the US, Germany, and UK support these distribution relationships.
  • University of Utah (Prof. Bruce Gale)foundationalStrategic or Co-development PartnerCarterra's patented flow printing technology was invented in the lab of Prof. Bruce Gale at the University of Utah Department of Mechanical Engineering. The technology uses a network of microchannels enabling flow-based array printing of proteins and antibodies on sensor surfaces.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Carterra competitors and assessment

Company assessment

Emerging players

  • Wasatch Microfluidics / University of Utah SPR spinouts: Academic and early-stage commercial groups continuing to innovate in SPR microfluidics and array-based biosensing (drawn from the same University of Utah ecosystem that birthed Carterra's flow-printing IP). These emerging entrants represent a long-tail competitive threat as SPR technology matures.

Broad incumbents

  • Bruker: Bruker manufactures a broad range of life-science analytical instruments including mass spectrometry and SPR systems, serving the same pharmaceutical and academic research customers as Carterra with a much larger and more diversified product portfolio.
  • Sartorius: Sartorius (including the legacy FortéBio Octet bio-layer interferometry line) competes with Carterra in label-free protein interaction analysis for antibody screening and bioprocess analytics, serving overlapping pharma/biotech customers with a broader bioprocessing portfolio.
  • Thermo Fisher Scientific: Thermo Fisher offers a wide suite of life-science instruments, consumables, and analytical tools used in drug discovery workflows. While not a direct SPR competitor, it sells alternative characterization and high-throughput screening platforms to the same pharma/biotech buyer base.
  • Agilent Technologies: Agilent provides analytical instruments (mass spectrometry, chromatography, plate readers) used in pharmaceutical discovery and characterization. It competes with Carterra for share of biopharma R&D lab budgets and increasingly offers label-free and high-throughput screening solutions.
  • Revvity (formerly PerkinElmer Life Sciences): Revvity is both an integration partner of Carterra (Signals VitroVivo software) and a broader life-science instruments and reagents supplier, including the legacy PerkinElmer analytical portfolio. It competes for the same pharma discovery and screening budgets and provides complementary and overlapping analytical platforms.
  • Waters Corporation: Waters is a leading analytical instrument manufacturer (chromatography, mass spectrometry, sample management) used in pharmaceutical discovery and QC. It addresses overlapping biopharma R&D customers as Carterra, though with separation- and characterization-focused tools rather than SPR.

Direct peers

  • Cytiva (Biacore): Cytiva's Biacore line is the dominant surface plasmon resonance (SPR) platform in pharmaceutical and academic labs. As the incumbent in label-free biomolecular interaction analysis, Biacore directly competes with Carterra's LSA, LSAXT, Ultra, and Vega systems across the same pharma and biotech customer base.

Regional players

  • Molecular Devices: Molecular Devices (a Danaher operating company) offers microplate readers, washers, and label-free detection platforms used in drug discovery. Its label-free and high-throughput screening products compete with Carterra's HT-SPR for the same antibody screening and characterization workflows.

Others

  • Malvern Panalytical: Malvern Panalytical provides analytical instrumentation for material characterization, including particle sizing and molecular interaction tools. While it does not directly compete in HT-SPR, it addresses adjacent biophysical characterization needs for the same biotech and pharma R&D customers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Carterra social profiles

Digital presence

Carterra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Carterra leadership team

Management profile

Number of profiles

Profiles7 records

Carterra funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Carterra M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carterra

What does Carterra do?

Carterra develops, manufactures, and sells High-Throughput Surface Plasmon Resonance (HT-SPR) instruments — Carterra Vega, Ultra, LSAXT, and LSA — that enable parallel, label-free characterization of biomolecular interactions for antibody and small molecule drug discovery. The company also supplies proprietary biosensor sensor chips, printhead and SFC cartridges, and data analysis software (Kinetics, Epitope, Navigator) used by pharmaceutical, biotechnology, and AI drug discovery customers globally.

Is Carterra a public or private company?

Carterra is a private company. It is classified as venture growth investor backed and is currently operating.

When was Carterra founded?

Carterra was founded in 2005. It employs 51 to 100 people.

Where is Carterra based?

Carterra is headquartered in Salt Lake City, United States, in the North America region.

How does Carterra make money?

Four revenue lines are on record. HT-SPR Instrumentation Sales are the primary driver. The others are sensor Chips and Consumables, software Licenses and Updates and service, Support, and Training.

Who are Carterra's main competitors?

Wasatch Microfluidics / University of Utah SPR spinouts is listed as an emerging player. Broad incumbents are Bruker, Sartorius, Thermo Fisher Scientific, Agilent Technologies, Revvity (formerly PerkinElmer Life Sciences) and Waters Corporation. Cytiva (Biacore) is listed as a direct peer. Molecular Devices is listed as a regional player. Malvern Panalytical is listed as an others.

Does Carterra have an API?

No public API is recorded for Carterra.

What industry is Carterra in?

Carterra's product category is High-Throughput Surface Plasmon Resonance (HT-SPR) Instruments for Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogCarterra and Grenova Robotics Integrate Carterra Vega™ with KX2 Collaborative Robot to Create Automated HT-SPR Work CellCarterra and Grenova Robotics integrated Carterra Vega HT-SPR with KX2 collaborative robot to create an automated work cell for drug discovery labs. The system screens over 20,000 compounds daily unattended, delivering up to 12X throughput of other SPR instruments for small molecules.News-MedicalCarterra advances lab-in-the-loop drug discovery through new scientific collaborationCarterra announced a research collaboration with AstraZeneca to develop hardware and software for lab-in-the-loop drug discovery. The partnership aims to connect laboratory systems with AI-driven workflows, addressing data consistency barriers. The effort is part of a broader industry shift toward AI-enabled discovery.PharmaTimesCarterra supports AI‑designed protein study with HT-SPR platformsCarterra's high-throughput surface plasmon resonance platforms validated 1,320 AI-designed protein binders across 15 targets, with Anthropic and Adaptyv using the systems. The study showed AI-generated binders in days, with one binder measured at 3.9 nM versus 45 nM for a prior winner. Carterra's array-based approach compresses experiments into unattended runs using 1% of sample.Business Wire BlogLeerink Partners Report Names Carterra a Core Enabler of the $7B "Lab-in-the-Loop" Antibody Discovery MarketLeerink Partners published a report on July 16, 2026, identifying Carterra as a key enabling technology in the rapidly growing AI-driven biologics drug discovery market, which the firm estimates represents a $7 billion total addressable market in life science tools demand. The "Lab-in-the-Loop" paradigm described in the report relies on high-throughput wet lab validation of AI-proposed antibody candidates, with binding affinity measurement emerging as a critical bottleneck that should drive sustained demand for Carterra's SPR platforms. Carterra CEO Josh Eckman and customers Twist Bioscience and Adaptyv Bio cited the platform's role in generating the high-volume binding data sets required for modern AI-guided discovery programs.PR Newswire APACACROBiosystems collaborates with Carterra, accelerating large-scale characterization of potential drug candidatesACROBiosystems and Carterra announced a collaboration to use FLAG multi-pass transmembrane proteins and Carterra's LSA platform for high-throughput surface plasmon resonance screening of drug candidates. The approach targets undruggable transmembrane proteins like CD20 and Claudin18.2, enabling rapid characterization of thousands of candidates.openPR.comMarket Trend Analysis: The Impact of Recent Innovations on the Surface Plasmon Resonance MarketThe surface plasmon resonance market is projected to reach $2.3 billion by 2030, growing at a compound annual growth rate of 11.5%, driven by increased applications in biologics, personalized medicine, and drug discovery. In October 2024, Bruker Corporation completed the acquisition of Dynamic Biosensors GmbH, a Germany-based biosensor technology company, to strengthen its portfolio in biophysical instruments. Additionally, U.S.-based Carterra introduced its LSA XT high-throughput SPR platform in February 2023, offering improved sensitivity and sample throughput for pharmaceutical and biotech companies.National TodayCarterra Named Top Life Science Tools Provider for AI Drug DiscoveryWilliam Blair analysts named Carterra, a Salt Lake City-based life science tools company, as a top provider positioned to benefit from the growing adoption of AI in early drug discovery workflows. The analysts highlighted Carterra's high-throughput surface plasmon resonance (HT-SPR) technology platforms as key enablers for generating the large experimental datasets needed to train and validate AI drug discovery models. The analysis was published on April 8, 2026.PharmiWeb.comWilliam Blair Analysts Name Carterra a Winner in Life Science Tools for Enabling AI Drug Discovery at Unprecedented ScaleWilliam Blair analysts published a white paper analyzing how AI is reshaping drug discovery and named Carterra a "Winner" among life science technology providers enabling AI-driven workflows. The analysts concluded that wet lab experiments will likely increase rather than decrease as AI adoption grows, and identified Carterra's high-throughput surface plasmon resonance (HT-SPR) technology as a means to capitalize on the massive screening and characterization data required in AI workflows. Carterra's newest platform Vega, launched in early 2026, enables screening of more than 20,000 small molecule compounds per day, an order of magnitude greater than existing technologies.EIN PresswireMosaic Biosciences Expands Discovery Capabilities with Carterra® High-Throughput SPR PlatformMosaic Biosciences, a biologics discovery company, announced the addition of a Carterra high-throughput surface plasmon resonance (HT-SPR) instrument to its discovery platform to enhance capabilities for antibody and protein therapeutic development. The Carterra LSAXT technology enables rapid, high-sensitivity analysis of protein-protein and antibody-antigen interactions with industry-leading throughput, supporting lead identification and candidate selection across oncology, immunology, and rare disease programs. The technology will be incorporated immediately into Mosaic's discovery pipelines to strengthen collaborative programs with partners and improve candidate selection processes.Precedence ResearchHigh Throughput Screening (HTS) Market Growth and InsightsThe global high throughput screening market is projected to grow from USD 25.55 billion in 2025 to USD 71.11 billion by 2035, representing a compound annual growth rate of 10.78%. The market growth is driven by increasing focus on drug repurposing, rising research funding, growing chronic disease prevalence, and collaborations between pharmaceutical firms, research institutions, and technology providers. On March 5, 2026, Carterra launched the Vega high-throughput surface plasmon resonance platform, the first 48-channel SPR system for label-free biomolecular screening, capable of analyzing over 20,000 small-molecule interactions daily.